Responsibility in Drug Advertising Act of 2025

HR 1117, the Responsibility in Drug Advertising Act of 2025, prohibits drug manufacturers from running direct-to-consumer advertisements for newly approved drugs during the first three years after approval, including on social media platforms. Manufacturers may apply for a waiver during the third year if they demonstrate the ads would provide public health benefits. After the initial three years, the FDA may ban such advertising if post-approval safety data shows significant health risks. This bill directly affects pharmaceutical companies by restricting their marketing practices for new drugs, while aiming to limit consumer exposure to potentially risky medications before full safety data is available.